← All trials
NCT07136922
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Oct 31, 2026
- Completion date
- Aug 31, 2027
- First posted
- Aug 22, 2025
- Last posted
- Aug 22, 2025
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Calla Lily Clinical Care LtdLead sponsor
- University of WarwickCollaborator
- University of WarwickCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.